Utilize este identificador para referenciar este registo:
http://hdl.handle.net/10362/129670| Título: | Enhancing Discovery of Genetic Variants for Posttraumatic Stress Disorder Through Integration of Quantitative Phenotypes and Trauma Exposure Information |
| Autor: | Maihofer, Adam X. Choi, Karmel W. Coleman, Jonathan R.I. Daskalakis, Nikolaos P. Denckla, Christy A. Ketema, Elizabeth Morey, Rajendra A. Polimanti, Renato Ratanatharathorn, Andrew Torres, Katy Wingo, Aliza P. Austin, S. Bryn Avdibegović, Esmina Borglum, Anders D. Babić, Dragan Bækvad-Hansen, Marie Baker, Dewleen G. Beckham, Jean C. Bierut, Laura J. Bisson, Jonathan I. Boks, Marco P. McFarlane, Alexander Bolger, Elizabeth A. Bradley, Bekh Brashear, Meghan Breen, Gerome Bryant, Richard A. Bustamante, Angela C. Bybjerg-Grauholm, Jonas Calabrese, Joseph R. JM, Caldas-de-Almeida Chen, Chia Yen McGlinchey, Regina E. Dale, Anders M. Dalvie, Shareefa Deckert, Jürgen Delahanty, Douglas L. Dennis, Michelle F. Disner, Seth G. Domschke, Katharina Duncan, Laramie E. Džubur Kulenović, Alma Erbes, Christopher R. McLaughlin, Katie A. Evans, Alexandra Farrer, Lindsay A. Feeny, Norah C. Flory, Janine D. Forbes, David Franz, Carol E. Galea, Sandro Garrett, Melanie E. Gautam, Aarti Gelaye, Bizu McLean, Samuel A. Gelernter, Joel Geuze, Elbert Gillespie, Charles F. Goçi, Aferdita Gordon, Scott D. Guffanti, Guia Hammamieh, Rasha Hauser, Michael A. Heath, Andrew C. Hemmings, Sian M.J. Mehta, Divya Hougaard, David Michael Jakovljević, Miro Jett, Marti Johnson, Eric Otto Jones, Ian Jovanovic, Tanja Qin, Xue Jun Karstoft, Karen Inge Kaufman, Milissa L. Kessler, Ronald Mellor, Rebecca Khan, Alaptagin Kimbrel, Nathan A. King, Anthony P. Koen, Nastassja Kranzler, Henry R. Kremen, William S. Lawford, Bruce R. Lebois, Lauren A.M. Lewis, Catrin Liberzon, Israel Michopoulos, Vasiliki Linnstaedt, Sarah D. Logue, Mark W. Lori, Adriana Lugonja, Božo Luykx, Jurjen J. Lyons, Michael J. Maples-Keller, Jessica L. Marmar, Charles Martin, Nicholas G. Maurer, Douglas Milberg, William Mavissakalian, Matig R. Miller, Mark W. Morris, Charles Phillip Zai, Clement C. Mors, Ole Mortensen, Preben B. Nelson, Elliot C. Nordentoft, Merete Norman, Sonya B. O'Donnell, Meaghan Orcutt, Holly K. Panizzon, Matthew S. Peters, Edward S. Peterson, Alan L. Aiello, Allison E. Peverill, Matthew Pietrzak, Robert H. Polusny, Melissa A. Rice, John P. Risbrough, Victoria B. Roberts, Andrea L. Rothbaum, Alex O. Rothbaum, Barbara O. Roy-Byrne, Peter Ruggiero, Kenneth J. Almli, Lynn M. Rung, Ariane Rutten, Bart P.F. Saccone, Nancy L. Sanchez, Sixto E. Schijven, Dick Seedat, Soraya Seligowski, Antonia V. Seng, Julia S. Sheerin, Christina M. Silove, Derrick Amstadter, Ananda B. Smith, Alicia K. Smoller, Jordan W. Sponheim, Scott R. Stein, Dan J. Stevens, Jennifer S. Teicher, Martin H. Thompson, Wesley K. Trapido, Edward Uddin, Monica Ursano, Robert J. Andersen, Soren B. van den Heuvel, Leigh Luella Van Hooff, Miranda Vermetten, Eric Vinkers, Christiaan Voisey, Joanne Wang, Yunpeng Wang, Zhewu Werge, Thomas Williams, Michelle A. Williamson, Douglas E. Andreassen, Ole A. Winternitz, Sherry Wolf, Christiane Wolf, Erika J. Yehuda, Rachel Young, Keith A. Young, Ross Mc D. Zhao, Hongyu Zoellner, Lori A. Haas, Magali Lasseter, Heather Arbisi, Paul A. Provost, Allison C. Salem, Rany M. Sebat, Jonathan Shaffer, Richard A. Wu, Tianying Ripke, Stephan Daly, Mark J. Ressler, Kerry J. Koenen, Karestan C. Stein, Murray B. Ashley-Koch, Allison E. Nievergelt, Caroline M. |
| Palavras-chave: | Genetics GWAS Heritability PheWAS PTSD Trauma Biological Psychiatry |
| Data: | 1-Abr-2022 |
| Resumo: | Background: Posttraumatic stress disorder (PTSD) is heritable and a potential consequence of exposure to traumatic stress. Evidence suggests that a quantitative approach to PTSD phenotype measurement and incorporation of lifetime trauma exposure (LTE) information could enhance the discovery power of PTSD genome-wide association studies (GWASs). Methods: A GWAS on PTSD symptoms was performed in 51 cohorts followed by a fixed-effects meta-analysis (N = 182,199 European ancestry participants). A GWAS of LTE burden was performed in the UK Biobank cohort (N = 132,988). Genetic correlations were evaluated with linkage disequilibrium score regression. Multivariate analysis was performed using Multi-Trait Analysis of GWAS. Functional mapping and annotation of leading loci was performed with FUMA. Replication was evaluated using the Million Veteran Program GWAS of PTSD total symptoms. Results: GWASs of PTSD symptoms and LTE burden identified 5 and 6 independent genome-wide significant loci, respectively. There was a 72% genetic correlation between PTSD and LTE. PTSD and LTE showed largely similar patterns of genetic correlation with other traits, albeit with some distinctions. Adjusting PTSD for LTE reduced PTSD heritability by 31%. Multivariate analysis of PTSD and LTE increased the effective sample size of the PTSD GWAS by 20% and identified 4 additional loci. Four of these 9 PTSD loci were independently replicated in the Million Veteran Program. Conclusions: Through using a quantitative trait measure of PTSD, we identified novel risk loci not previously identified using prior case-control analyses. PTSD and LTE have a high genetic overlap that can be leveraged to increase discovery power through multivariate methods. |
| Descrição: | Funding Information: This work was supported by the National Institute of Mental Health / U.S. Army Medical Research and Development Command (Grant No. R01MH106595 [to CMN, IL, MBS, KJRe, and KCK], National Institutes of Health (Grant No. 5U01MH109539 to the Psychiatric Genomics Consortium ), and Brain & Behavior Research Foundation (Young Investigator Grant [to KWC]). Genotyping of samples was provided in part through the Stanley Center for Psychiatric Genetics at the Broad Institute supported by Cohen Veterans Bioscience . Statistical analyses were carried out on the LISA/Genetic Cluster Computer ( https://userinfo.surfsara.nl/systems/lisa ) hosted by SURFsara. This research has been conducted using the UK Biobank resource (Application No. 41209). This work would have not been possible without the financial support provided by Cohen Veterans Bioscience, the Stanley Center for Psychiatric Genetics at the Broad Institute, and One Mind. Funding Information: MBS has in the past 3 years received consulting income from Actelion, Acadia Pharmaceuticals, Aptinyx, Bionomics, BioXcel Therapeutics, Clexio, EmpowerPharm, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and Roche/Genentech and has stock options in Oxeia Biopharmaceuticals and Epivario. In the past 3 years, NPD has held a part-time paid position at Cohen Veterans Bioscience, has been a consultant for Sunovion Pharmaceuticals, and is on the scientific advisory board for Sentio Solutions for unrelated work. In the past 3 years, KJRe has been a consultant for Datastat, Inc., RallyPoint Networks, Inc., Sage Pharmaceuticals, and Takeda. JLM-K has received funding and a speaking fee from COMPASS Pathways. MU has been a consultant for System Analytic. HRK is a member of the Dicerna scientific advisory board and a member of the American Society of Clinical Psychopharmacology Alcohol Clinical Trials Initiative, which during the past 3 years was supported by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Dicerna, Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka. HRK and JG are named as inventors on Patent Cooperative Treaty patent application number 15/878,640, entitled “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. RP and JG are paid for their editorial work on the journal Complex Psychiatry. OAA is a consultant to HealthLytix. All other authors report no biomedical financial interests or potential conflicts of interest. Funding Information: This work was supported by the National Institute of Mental Health/ U.S. Army Medical Research and Development Command (Grant No. R01MH106595 [to CMN, IL, MBS, KJRe, and KCK], National Institutes of Health (Grant No. 5U01MH109539 to the Psychiatric Genomics Consortium), and Brain & Behavior Research Foundation (Young Investigator Grant [to KWC]). Genotyping of samples was provided in part through the Stanley Center for Psychiatric Genetics at the Broad Institute supported by Cohen Veterans Bioscience. Statistical analyses were carried out on the LISA/Genetic Cluster Computer (https://userinfo.surfsara.nl/systems/lisa) hosted by SURFsara. This research has been conducted using the UK Biobank resource (Application No. 41209). This work would have not been possible without the financial support provided by Cohen Veterans Bioscience, the Stanley Center for Psychiatric Genetics at the Broad Institute, and One Mind. This material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting true views of the U.S. Department of the Army or the Department of Defense. We thank the investigators who comprise the PGC-PTSD working group and especially the more than 206,000 research participants worldwide who shared their life experiences and biological samples with PGC-PTSD investigators. We thank Mark Zervas for his critical input. Full acknowledgments are in Supplement 1. MBS has in the past 3 years received consulting income from Actelion, Acadia Pharmaceuticals, Aptinyx, Bionomics, BioXcel Therapeutics, Clexio, EmpowerPharm, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and Roche/Genentech and has stock options in Oxeia Biopharmaceuticals and Epivario. In the past 3 years, NPD has held a part-time paid position at Cohen Veterans Bioscience, has been a consultant for Sunovion Pharmaceuticals, and is on the scientific advisory board for Sentio Solutions for unrelated work. In the past 3 years, KJRe has been a consultant for Datastat, Inc. RallyPoint Networks, Inc. Sage Pharmaceuticals, and Takeda. JLM-K has received funding and a speaking fee from COMPASS Pathways. MU has been a consultant for System Analytic. HRK is a member of the Dicerna scientific advisory board and a member of the American Society of Clinical Psychopharmacology Alcohol Clinical Trials Initiative, which during the past 3 years was supported by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Dicerna, Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka. HRK and JG are named as inventors on Patent Cooperative Treaty patent application number 15/878,640, entitled ?Genotype-guided dosing of opioid agonists,? filed January 24, 2018. RP and JG are paid for their editorial work on the journal Complex Psychiatry. OAA is a consultant to HealthLytix. All other authors report no biomedical financial interests or potential conflicts of interest. Publisher Copyright: © 2021 Society of Biological Psychiatry |
| Peer review: | yes |
| URI: | http://hdl.handle.net/10362/129670 |
| DOI: | https://doi.org/10.1016/j.biopsych.2021.09.020 |
| ISSN: | 0006-3223 |
| Aparece nas colecções: | NMS: CEDOC - Artigos em revista internacional com arbitragem científica |
Ficheiros deste registo:
| Ficheiro | Descrição | Tamanho | Formato | |
|---|---|---|---|---|
| 1_s2.0_S0006322321016322_main.pdf | 931,35 kB | Adobe PDF | Ver/Abrir |
Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.











